Phase I trial of sargramostim in pediatric Crohn's disease

✍ Scribed by Judith R. Kelsen; Joel Rosh; Mel Heyman; Harland S. Winter; George Ferry; Stanley Cohen; Petar Mamula; Robert N. Baldassano

• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 178 KB
• Volume: 16
• Category: Article
• ISSN: 1078-0998
• DOI: 10.1002/ibd.21204

✦ Synopsis

Background: Improving granulocyte function may represent an effective therapy for Crohn's disease (CD). We performed a Phase I-2 trial of sargramostim (SRG) in children with CD.

Methods: This was multicenter, open-label study in 6-16-yearold patients with moderate to severely active CD. Patients received either 4 or 6 lg/kg SRG subcutaneously daily for 8 weeks, with and without concomitant corticosteroids (CS). The primary endpoint was identification of a safe and tolerable dose in children. The secondary endpoint was establishment of the pharmacokinetics (PK). Efficacy, a tertiary endpoint, was measured by the Pediatric CD Activity Index (PCDAI). Response was defined as a decrease from baseline of !12.5 points and remission as absolute PCDAI of 10.

Results: In all, 22 patients were enrolled: 12 and 10 received 4 and 6 mg/kg, respectively; 19 completed the course. Both doses were found to be safe and well tolerated. Mild injection-site reactions occurred in 90% of patients. Three patients required dose reductions due to elevated absolute neutrophil counts. Following 4 lg/kg the mean area under the curve (AUC) was 2.64 and 2.80 ngh/mL for the 6-11-and 12-16-year-old groups, respectively. The mean half-life (t 1/2 ) was 1.22 and 1.59 hours, respectively. Following 6 lg/kg, the mean AUC was 5.01 ngh/mL for the 12-16-year-old group, a 1.8-fold increase. A total of 16/18 patients (88%) achieved remission or response.

Conclusions: Sargramostim at both 4 and 6 mg/kg was well tolerated. PK analysis suggested dose proportionality unaffected by CS exposure. Remission and response data are encouraging, but further trials are needed to assess efficacy.